SAFETYLIT WEEKLY UPDATE

We compile citations and summaries of about 400 new articles every week.
RSS Feed

HELP: Tutorials | FAQ
CONTACT US: Contact info

Search Results

Journal Article

Citation

Mori AT, Meena E, Kaale EA. BMJ Open 2018; 8(6): e021825.

Affiliation

School of Pharmacy, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.

Copyright

(Copyright © 2018, BMJ Publishing Group)

DOI

10.1136/bmjopen-2018-021825

PMID

29950474

PMCID

PMC6020956

Abstract

OBJECTIVE: To estimate the economic cost of substandard and falsified human medicines and cosmetics with banned ingredients in Tanzania from 2005 to 2015.

DESIGN: A retrospective review of data. SETTING: Tanzania Food and Drugs Authority and premises dealing with importations and distributions of pharmaceuticals. ELIGIBILITY CRITERIA: Confiscation reports of substandard human medicines, falsified human medicines and cosmetics with banned ingredients. PRIMARY AND SECONDARY OUTCOME MEASURES: Quantities and costs of pharmaceutical products, costs of transportation, storage, court cases and disposal of products.

RESULTS: The economic cost of substandard and falsified human medicines and cosmetics with banned ingredients was estimated at US$16.2 million, that is, value of substandard medicines US$13.7 million (84.4%), falsified medicines US$0.1 million (1%), cosmetics with banned ingredients US$1.3 million (8%) and other/operational costs US$1.1 million (6.6%). Some of the identified substandard and falsified human medicines include commonly used antibiotics such as phenoxymethylpenicillin, amoxicillin, cloxacillin and co-trimoxazole; antimalarials such quinine, sulfadoxine-pyrimethamine, sulfamethoxypyrazine-pyrimethamine and artemether-lumefantrine; antiretroviral drugs; antipyretics and vitamins among others.

CONCLUSION: The economic cost of substandard and falsified human medicines and cosmetics with banned ingredients represent a relatively large loss of scarce resources for a poor country like Tanzania. We believe that the observed increase in the quantities and the economic cost of these products over time could partly be due to the improvement in the regulatory capacity in terms of human resources, infrastructure and frequency of inspections.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.


Language: en

Keywords

health economics; public health

NEW SEARCH


All SafetyLit records are available for automatic download to Zotero & Mendeley
Print